The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

Medical Oncology

Volumn 26, Issue 3, 2009, Pages 350-357

  Sezer, Atakan ^a   Usta, Ufuk ^a   Cicin, Irfan ^a,b  

^a TRAKYA UNIVERSITY   (Turkey)

^b Elazig Military Hospital   (Turkey)

Author keywords

Diarrhea; Irinotecan; Mucositis; Saccharomyces boulardii

Indexed keywords

FUNGAL EXTRACT; IRINOTECAN; REFLOR SASE; SACCHAROMYCES BOULARDII EXTRACT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; ENTERITIS; HISTOPATHOLOGY; INTESTINAL MUCOSITIS; JEJUNUM; LEUKOCYTE MIGRATION; MALE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; RISK REDUCTION; SACCHAROMYCES BOULARDII; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; HISTOCYTOCHEMISTRY; LEUKOCYTES; MUCOSITIS; RATS; SACCHAROMYCES; WEIGHT LOSS;

EID: 77952653193     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9128-1     Document Type: Article

References (44)

1. A Tanizawa A Fujimori Y Fujimori Y Pommier 1994 Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J Natl Cancer Inst (Bethesda) 86 836 42 10.1093/jnci/86.11.836 10.1093/jnci/86.11.836 1:CAS:528:DyaK2cXlvFGiu74%3D
2. JY Douillard, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for colorectal cancer: a multicenter randomized trial Lancet 355 1041 7 10.1016/S0140-6736(00)02034-1 10744089 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D
3. SH Park, et al. 2008 Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer Ann Oncol 19 729 33 10.1093/annonc/mdm502 18083691 10.1093/annonc/mdm502 1:STN:280: DC%2BD1c3gsVOrtw%3D%3D (Pubitemid 351461044)
4. N Hanna, et al. 2006 Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer J Clin Oncol 24 2038 43 10.1200/JCO.2005.04.8595 16648503 10.1200/JCO.2005.04.8595 1:CAS:528: DC%2BD28Xlt1amuro%3D (Pubitemid 46622112)
5. FM Muggia JA Blessing R McGehee BJ Monk 2004 Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group Gynecol Oncol 94 483 7 10.1016/j.ygyno.2004.05.018 15297192 10.1016/j.ygyno.2004.05.018 1:CAS:528:DC%2BD2cXmsVeqt7c%3D (Pubitemid 39024557)
6. V Ribrag, et al. 2003 Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas Leuk Lymphoma 44 1529 33 10.1080/1042819031000099643 14565655 10.1080/1042819031000099643 1:CAS:528:DC%2BD3sXmtFals7c%3D (Pubitemid 36833967)
7. AM Stringer, et al. 2007 Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment J Support Oncol 5 259 67 17624050 1:CAS:528:DC%2BD2sXnvFGjtr8%3D
8. RJ Gibson JM Bowen MR Inglis AG Cummins DM Keefe 2003 Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer J Gastroenterol Hepatol 18 1095 100 10.1046/j.1440-1746. 2003.03136.x 12911669 10.1046/j.1440-1746.2003.03136.x 1:CAS:528: DC%2BD3sXotlSmsLs%3D (Pubitemid 37175953)
9. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci. 2008 (in press).
10. CM Surawicz, et al. 1989 Prevention of antibiotic associated diarrhoea by Saccharomyces boulardii: a prospective study Gastroenterology 96 981 8 2494098 1:STN:280:DyaL1M7ntFyltQ%3D%3D
11. LV McFarland, et al. 1995 Prevention of -lactam associated diarrhoea by Saccharomyces boulardii compared with placebo Am J Gastroenterol 90 439 48 7872284 1:STN:280:DyaK2M7nslWhtA%3D%3D
12. LV McFarland, et al. 1994 A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease JAMA 271 1913 8 10.1001/jama.271.24.1913 8201735 10.1001/jama.271.24.1913 1:STN:280:DyaK2c3mtVKksQ%3D%3D (Pubitemid 24177098)
13. CM Surawicz, et al. 2000 The search for a better treatment for Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii Clin Infect Dis 31 1012 7 10.1086/318130 11049785 10.1086/318130 1:CAS:528:DC%2BD3cXos1yrt78%3D (Pubitemid 32299362)
14. JP Buts G Corthier M Delm'ee 1993 Saccharomyces boulardii for Clostridium difficile-associated enterocolopathies in infants J Pediatr Gastroenterol Nutr 16 1497 504 10.1097/00005176-199305000-00013
15. W Höchter D Chase G Hegenhoff 1990 Saccharomyces boulardii in treatment of acute adult diarrhoea efficacy and tolerance of treatment Münch Med Wochenschr 132 188 92
16. H Kollaritsch H Holst P Grobara G Wiedermann 1993 Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study Forstchr Med 111 152 6 1:STN:280: DyaK3s3lt1ehug%3D%3D
17. G Bleichner H Bléhaut H Mentec D Moyse 1997 Sacchromyces boulardii prevents diarrhoea in critically ill tube-fed patients. A multicenter, randomized, double-blind-placebo-controlled trial Intensive Care Med 23 517 23 10.1007/s001340050367 9201523 10.1007/s001340050367 1:STN:280: DyaK2szksFWmtA%3D%3D (Pubitemid 27263063)
18. T Saint-Marc H Bl'ehaut C Musial JL Touraine 1991 Efficacit'e de Saccharomyces boulardii dans le traitement des diarrh'ees du SIDA Am Med Int 142 64 5 1:STN:280:DyaK3M3msVCntQ%3D%3D
19. M Guslandi G Mezzi M Sorghi PA Testoni 2000 Saccharomyces boulardii in maintenance treatment of Crohn's disease Dig Dis Sci 45 1462 4 10.1023/A:1005588911207 10961730 10.1023/A:1005588911207 1:STN:280: DC%2BD3cvislamsA%3D%3D (Pubitemid 30636526)
20. M Guslandi P Giollo PA Testoni 2003 A pilot trial of Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 697 8 10.1097/00042737-200306000-00017 12840682 10.1097/00042737-200306000-00017 (Pubitemid 36688235)
21. C Pothoulakis, et al. 1993 Saccharomyces boulardii inhibits Clostridium difficile toxin. A binding and enterotoxicity in rat ileum Gastroenterology 104 1108 15 8462799 1:CAS:528:DyaK3sXktVKisbs%3D
22. D Czerucka I Roux P Rampal 1994 Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells Gastroenterology 106 65 72 8276210 1:CAS:528: DyaK2cXhs1Sgtbs%3D
23. D Czerucka P Rampal 1994 Effect of Saccharomyces boulardii on cAMP- and Ca2+-dependent Cl-secretion in T84 cells Dig Dis Sci 44 2359 68 10.1023/A:1026689628136 10.1023/A:1026689628136
24. D Czerucka S Dahan B Mograbi B Rossi P Rampal 2000 Saccharomyces boulardii preserves the barrier function and modulates the transduction pathway induced in enteropathogenic Escherichia coli infected T84 cells Infect Immun 68 5998 6004 10.1128/IAI.68.10.5998-6004.2000 10992512 10.1128/IAI.68.10.5998-6004. 2000 1:CAS:528:DC%2BD3cXmvVGnt7Y%3D
25. S Dahan, et al. 2003 Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli induced signalling pathways in T84 cells Infect Immun 71 766 73 10.1128/IAI.71.2.766-773.2003 12540556 10.1128/IAI.71.2.766-773.2003 1:CAS:528:DC%2BD3sXovFSmtA%3D%3D (Pubitemid 36150770)
26. G Dalmasso, et al. 2006 Saccharomyces boulardii prevents TNFa-induced apoptosis in EHEC-infected T84 cells Res Microbiol 157 456 66 10.1016/j.resmic.2005.11.007 16487684 10.1016/j.resmic.2005.11.007 1:CAS:528:DC%2BD28XltlKmur0%3D (Pubitemid 43833214)
27. A Qamar, et al. 2001 Saccharomyces boulardii stimulates intestinal immunoglobulin. A immune response to Clostridium difficile toxin A in mice Infect Immun 69 2762 5 10.1128/IAI.69.4.2762-2765.2001 11254650 10.1128/IAI.69.4.2762-2765.2001 1:CAS:528:DC%2BD3MXisVSltLY%3D (Pubitemid 32239759)
28. F Powrie MW Leach S Mauze LB Caddle RL Coffman 1993 Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in CB-17 scid mice Int Immunol 5 1461 71 10.1093/intimm/5.11.1461 7903159 10.1093/intimm/5.11.1461 1:STN:280:DyaK2c%2Fotlektg%3D%3D
29. Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci. 2008 (in press).
30. S Sougioultzis, et al. 2006 Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression Biochem Biophys Res Commun 34 69 76 10.1016/j.bbrc.2006.02.080 10.1016/j.bbrc.2006.02.080 1:CAS:528:DC%2BD28XivVOjsLY%3D
31. JP Buts N De Keyser 2006 Effects of Saccharomyces boulardii on intestinal mucosa Dig Dis Sci 51 1485 92 10.1007/s10620-005-9016-x 16838119 10.1007/s10620-005-9016-x (Pubitemid 44315819)
32. K Takasuna, et al. 2006 Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea Cancer Chemother Pharmacol 58 494 503 10.1007/s00280-006-0187-8 16437251 10.1007/s00280-006-0187-8 1:CAS:528:DC%2BD28XmsVShtL0%3D (Pubitemid 43999798)
33. RM Logan, et al. 2008 Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis Cancer Chemother Pharmacol 62 33 41 10.1007/s00280-007-0570-0 17703303 10.1007/s00280-007-0570-0 1:CAS:528:DC%2BD1cXks1Krsb8%3D (Pubitemid 351537842)
34. RJ Gibson DM Keefe 2006 Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies Support Care Cancer 14 890 900 10.1007/s00520-006-0040-y 16604351 10.1007/s00520-006-0040-y
35. K Takasuna, et al. 1996 Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats Cancer Res 56 3752 7 8706020 1:CAS:528:DyaK28XltVKksL4%3D
36. DF Kehrer, et al. 2001 Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res 7 1136 41 11350876 1:CAS:528:DC%2BD3MXktlemurY%3D
37. G Dalmasso, et al. 2006 Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes Gastroenterology 131 1812 25 10.1053/j.gastro.2006.10.001 17087945 10.1053/j.gastro.2006.10.001 1:CAS:528:DC%2BD2sXhtFyltb8%3D (Pubitemid 46001395)
38. JP Buts P Bernasconi MP Van Craynest P Maldague R De Meyer 1986 Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii Pediatr Res 20 192 6 10.1203/00006450-198602000-00020 3080730 10.1203/00006450-198602000-00020 1:CAS:528:DyaL28XhtVajs7Y%3D
39. HU Jahn, et al. 1996 Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers Digestion 57 95 104 8786007 10.1159/000201320 1:STN:280:DyaK283mt1Cjsw%3D%3D
40. HK Harms RM Bertele-Harms D Bruer-Kleis 1987 Enzyme substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase isomaltase deficiency N Engl J Med 316 1306 9 3553946 1:STN:280:DyaL2s3gtFOksg%3D%3D
41. JP Buts N De Keyser C Stilmant E Sokal S Marandi 2002 Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc binding metalloprotease Pediatr Res 51 528 34 10.1203/00006450-200204000-00021 11919341 10.1203/00006450-200204000-00021 1:CAS:528:DC%2BD38XjtFSgsbc%3D
42. JP Buts, et al. 1999 Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats Gut 45 89 96 10369710 1:STN:280: DyaK1M3pvVahsA%3D%3D
43. B Baum EM Liebler-Tenorio ML Enss JF Pohlenz G Breves 2002 Saccharomyces boulardii and Bacillus cereus var. Toyoi influence the morphology and the mucins of the intestine of pigs Z Gastroenterol 40 277 84 10.1055/s-2002-30116 12016561 10.1055/s-2002-30116 1:CAS:528:DC%2BD38XltFars7k%3D (Pubitemid 34595879)
44. V De Preter, et al. 2008 Effect of dietary intervention with different pre- and pro-biotics on intestinal bacterial enzyme activities Eur J Clin Nutr 62 225 31 10.1038/sj.ejcn.1602706 17327863 10.1038/sj.ejcn.1602706 1:CAS:528:DC%2BD1cXhs1KqtLY%3D (Pubitemid 351234257)